What's new

Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated angioedema, 25/03/2025 Positive

Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated angioedema, 25/03/2025 Positive

Apr 4, 2025 - 11:33
 0
Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated angioedema, 25/03/2025 Positive
Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated angioedema, 25/03/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: Felzartamab Treatment of in solid organ transplantation, 13/...

Next Article

Astronergy, four Turkish PV manufacturers to invest US$2.5 billion in solar cell...

Related Posts

DARWIN EU data partners onboarded in phases I, II and III

Feb 20, 2025  0

Clinical Trial Information System (CTIS) structured dat...

Mar 18, 2025  0

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 14, 2025  0